Lysosomal Pathogenesis of Parkinson’s Disease: Insights From LRRK2 and GBA1 Rodent Models

被引:0
|
作者
Mattia Volta
机构
[1] Eurac Research - Affiliated Institute of the University of Lübeck,Institute for Biomedicine
关键词
LRRK2; Glucocerebrosidase; Lysosomes; Parkinson’s disease; Animal models; Neuropathology;
D O I
暂无
中图分类号
学科分类号
摘要
The discovery of mutations in LRRK2 and GBA1 that are linked to Parkinson’s disease provided further evidence that autophagy and lysosome pathways are likely implicated in the pathogenic process. Their protein products are important regulators of lysosome function. LRRK2 has kinase-dependent effects on lysosome activity, autophagic efficacy and lysosomal Ca2+ signaling. Glucocerebrosidase (encoded by GBA1) is a hydrolytic enzyme contained in the lysosomes and contributes to the degradation of alpha-synuclein. PD-related mutations in LRRK2 and GBA1 slow the degradation of alpha-synuclein, thus directly implicating the dysfunction of the process in the neuropathology of Parkinson’s disease. The development of genetic rodent models of LRRK2 and GBA1 provided hopes of obtaining reliable preclinical models in which to study pathogenic processes and perform drug validation studies. Here, I will review the extensive characterization of these models, their impact on understanding lysosome alterations in the course of Parkinson’s disease and what novel insights have been obtained. In addition, I will discuss how these models fare with respect to the features of a “gold standard” animal models and what could be attempted in future studies to exploit LRRK2 and GBA1 rodent models in the fight against Parkinson’s disease.
引用
收藏
页码:127 / 139
页数:12
相关论文
共 50 条
  • [2] Mild cognitive impairment among LRRK2 and GBA1 patients with Parkinson's disease
    Thaler, Avner
    Livne, Vered
    Rubinstein, Einat
    Omer, Nurit
    Faust-Socher, Achinoam
    Cohen, Batsheva
    Giladi, Nir
    Shirvan, Julia C.
    Cedarbaum, Jesse M.
    Gana-Weisz, Mali
    Goldstein, Orly
    Orr-Urtreger, Avi
    Alcalay, Roy N.
    Mirelman, Anat
    PARKINSONISM & RELATED DISORDERS, 2024, 123
  • [3] Studies on the possible interplay between GBA1 and LRRK2 genes in Parkinson disease using Drosophila models
    Serebryany, Vera
    Horowitz, Mia
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
  • [4] Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease
    Smith, Laura J.
    Lee, Chiao-Yin
    Menozzi, Elisa
    Schapira, Anthony H. V.
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [5] LRRK2, a puzzling protein: Insights into Parkinson's disease pathogenesis
    Esteves, A. Raquel
    Swerdlow, Russell H.
    Cardoso, Sandra M.
    EXPERIMENTAL NEUROLOGY, 2014, 261 : 206 - 216
  • [6] Levodopa-carbidopa intestinal gel for advanced Parkinson's ' s disease: Impact of LRRK2 and GBA1 mutations
    Thaler, Avner
    Anis, Saar
    Ponger, Penina
    Fay-Karmon, Tsviya
    Livneh, Vered
    Faust-Socher, Achinoam
    Greenbaum, Lior
    Reiner, Johnathan
    Hilel, Ariela
    Shabtai, Hertzel
    Alcalay, Roy N.
    Djaldetti, Ruth
    Hassin-Baer, Sharon
    Ezra, Adi
    Mirelman, Anat
    Giladi, Nir
    Gurevich, Tanya
    PARKINSONISM & RELATED DISORDERS, 2024, 127
  • [7] Lysosomal β-glucosidase (GBA1) and non-lysosomal β-glucosidase (GBA2): Potential involvement in the pathogenesis of Gaucher disease/Parkinson disease
    Burke, Derek G.
    Heales, Simon J.
    Vellodi, Ashok
    MOLECULAR GENETICS AND METABOLISM, 2015, 114 (02) : S26 - S26
  • [8] Comorbidities in Genetic Parkinson's disease (PD): Comparison Between LRRK2, GBA1, and Non-Mutated PD
    Di Rauso, G.
    Pirone, F.
    Franco, G.
    Arienti, F.
    Trezzi, I.
    Frattini, E.
    Cavallieri, F.
    Rispoli, V.
    Valzania, F.
    Monfrini, E.
    Di Fonzo, A.
    MOVEMENT DISORDERS, 2024, 39 : S773 - S773
  • [9] Sleep quality in GBA, LRRK2 and idiopathic Parkinson's disease
    Yoo, A.
    Ortega, R.
    Raymond, D.
    Plitnick, B.
    Markgraf, M.
    Liang, J.
    Rawal, M.
    Wise, A.
    Pullman, M.
    Leaver, K.
    Katsnelson, V.
    Miravite, J.
    Shanker, V.
    Swan, M.
    Figueiro, M.
    Bressman, S.
    Saunders-Pullman, R.
    MOVEMENT DISORDERS, 2023, 38 : S227 - S227
  • [10] The Influence of GBA and LRRK2 on Mood Disorders in Parkinson's Disease
    DeBroff, Jake
    Omer, Nurit
    Cohen, Batsheva
    Giladi, Nir
    Kestenbaum, Meir
    Shirvan, Julia C.
    Cedarbaum, Jesse M.
    Gana-Weisz, Mali
    Goldstein, Orly
    Orr-Urtreger, Avi
    Mirelman, Anat
    Thaler, Avner
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2023, 10 (04): : 606 - 616